Analysis of the safety evaluation for premarketing clinical trials of hemodialyzer and of postmarketing safety reports of hemodialyzer in Japan and the US

insights into the construction of a sophisticated premarketing evaluation

Masami Saito, Kiyotaka Iwasaki

    Research output: Contribution to journalArticle

    Abstract

    Our aim was to conduct a scoping review of the regulations for hemodialyzers in the safety evaluation in Japan and the United States, and to evaluate the criteria for premarketing clinical trials and postmarketing safety reports to inform the development of a sophisticated premarketing evaluation in Japan. Regulations for approval of hemodialyzers were identified from the databases of the Ministry of Health, Labor and Welfare in Japan and the Federal Drug Agency (FDA) in the United States (US). The criteria for premarket clinical trials and postmarketing safety reports were evaluated for both countries. Standards in Japan required evaluation of blood compatibility and reporting of acute adverse effects by a premarketing clinical trial in 6 of 86 applications with semipermeable membrane materials deemed to be different to those of previously approved devices from 1983 to 31 August 2015. By comparison, the clinical trial was required in one of 545 approvals in the US from 1976 to 29 January 2016, but blood compatibility was not the point. All postmarketing adverse effects identified in Japan were included in the set of ‘warnings’. The more stringent requirements for evaluation of blood compatibility and acute adverse effects in Japan seemed to be related to differences in the history of quality management systems for medical devices between the two countries. This study revealed that there were differences between Japan and the US in requiring the premarketing clinical trials for the hemodialyzers. Our findings could be useful for constructing sophisticated premarketing safety evaluation.

    Original languageEnglish
    Pages (from-to)1-9
    Number of pages9
    JournalJournal of Artificial Organs
    DOIs
    Publication statusAccepted/In press - 2016 Oct 5

    Fingerprint

    Hemodialyzers
    Artificial Kidneys
    Japan
    Clinical Trials
    Safety
    Blood
    Quality management
    Health
    Equipment and Supplies
    Personnel
    Membranes
    Pharmaceutical Preparations
    History
    Databases

    Keywords

    • Dialysis
    • Postmarketing evaluation
    • Premarketing evaluation
    • Regulatory science

    ASJC Scopus subject areas

    • Medicine (miscellaneous)
    • Biomaterials
    • Biomedical Engineering
    • Cardiology and Cardiovascular Medicine

    Cite this

    @article{880a64124de64a01a63e98f47a33982f,
    title = "Analysis of the safety evaluation for premarketing clinical trials of hemodialyzer and of postmarketing safety reports of hemodialyzer in Japan and the US: insights into the construction of a sophisticated premarketing evaluation",
    abstract = "Our aim was to conduct a scoping review of the regulations for hemodialyzers in the safety evaluation in Japan and the United States, and to evaluate the criteria for premarketing clinical trials and postmarketing safety reports to inform the development of a sophisticated premarketing evaluation in Japan. Regulations for approval of hemodialyzers were identified from the databases of the Ministry of Health, Labor and Welfare in Japan and the Federal Drug Agency (FDA) in the United States (US). The criteria for premarket clinical trials and postmarketing safety reports were evaluated for both countries. Standards in Japan required evaluation of blood compatibility and reporting of acute adverse effects by a premarketing clinical trial in 6 of 86 applications with semipermeable membrane materials deemed to be different to those of previously approved devices from 1983 to 31 August 2015. By comparison, the clinical trial was required in one of 545 approvals in the US from 1976 to 29 January 2016, but blood compatibility was not the point. All postmarketing adverse effects identified in Japan were included in the set of ‘warnings’. The more stringent requirements for evaluation of blood compatibility and acute adverse effects in Japan seemed to be related to differences in the history of quality management systems for medical devices between the two countries. This study revealed that there were differences between Japan and the US in requiring the premarketing clinical trials for the hemodialyzers. Our findings could be useful for constructing sophisticated premarketing safety evaluation.",
    keywords = "Dialysis, Postmarketing evaluation, Premarketing evaluation, Regulatory science",
    author = "Masami Saito and Kiyotaka Iwasaki",
    year = "2016",
    month = "10",
    day = "5",
    doi = "10.1007/s10047-016-0928-3",
    language = "English",
    pages = "1--9",
    journal = "Journal of Artificial Organs",
    issn = "1434-7229",
    publisher = "Springer Japan",

    }

    TY - JOUR

    T1 - Analysis of the safety evaluation for premarketing clinical trials of hemodialyzer and of postmarketing safety reports of hemodialyzer in Japan and the US

    T2 - insights into the construction of a sophisticated premarketing evaluation

    AU - Saito, Masami

    AU - Iwasaki, Kiyotaka

    PY - 2016/10/5

    Y1 - 2016/10/5

    N2 - Our aim was to conduct a scoping review of the regulations for hemodialyzers in the safety evaluation in Japan and the United States, and to evaluate the criteria for premarketing clinical trials and postmarketing safety reports to inform the development of a sophisticated premarketing evaluation in Japan. Regulations for approval of hemodialyzers were identified from the databases of the Ministry of Health, Labor and Welfare in Japan and the Federal Drug Agency (FDA) in the United States (US). The criteria for premarket clinical trials and postmarketing safety reports were evaluated for both countries. Standards in Japan required evaluation of blood compatibility and reporting of acute adverse effects by a premarketing clinical trial in 6 of 86 applications with semipermeable membrane materials deemed to be different to those of previously approved devices from 1983 to 31 August 2015. By comparison, the clinical trial was required in one of 545 approvals in the US from 1976 to 29 January 2016, but blood compatibility was not the point. All postmarketing adverse effects identified in Japan were included in the set of ‘warnings’. The more stringent requirements for evaluation of blood compatibility and acute adverse effects in Japan seemed to be related to differences in the history of quality management systems for medical devices between the two countries. This study revealed that there were differences between Japan and the US in requiring the premarketing clinical trials for the hemodialyzers. Our findings could be useful for constructing sophisticated premarketing safety evaluation.

    AB - Our aim was to conduct a scoping review of the regulations for hemodialyzers in the safety evaluation in Japan and the United States, and to evaluate the criteria for premarketing clinical trials and postmarketing safety reports to inform the development of a sophisticated premarketing evaluation in Japan. Regulations for approval of hemodialyzers were identified from the databases of the Ministry of Health, Labor and Welfare in Japan and the Federal Drug Agency (FDA) in the United States (US). The criteria for premarket clinical trials and postmarketing safety reports were evaluated for both countries. Standards in Japan required evaluation of blood compatibility and reporting of acute adverse effects by a premarketing clinical trial in 6 of 86 applications with semipermeable membrane materials deemed to be different to those of previously approved devices from 1983 to 31 August 2015. By comparison, the clinical trial was required in one of 545 approvals in the US from 1976 to 29 January 2016, but blood compatibility was not the point. All postmarketing adverse effects identified in Japan were included in the set of ‘warnings’. The more stringent requirements for evaluation of blood compatibility and acute adverse effects in Japan seemed to be related to differences in the history of quality management systems for medical devices between the two countries. This study revealed that there were differences between Japan and the US in requiring the premarketing clinical trials for the hemodialyzers. Our findings could be useful for constructing sophisticated premarketing safety evaluation.

    KW - Dialysis

    KW - Postmarketing evaluation

    KW - Premarketing evaluation

    KW - Regulatory science

    UR - http://www.scopus.com/inward/record.url?scp=84990849785&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84990849785&partnerID=8YFLogxK

    U2 - 10.1007/s10047-016-0928-3

    DO - 10.1007/s10047-016-0928-3

    M3 - Article

    SP - 1

    EP - 9

    JO - Journal of Artificial Organs

    JF - Journal of Artificial Organs

    SN - 1434-7229

    ER -